{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:24:09Z","timestamp":1793798649539,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR203331"],"award-info":[{"award-number":["NIHR203331"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["arthroplastytoday.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arthroplasty Today"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.artd.2025.101840","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T01:40:27Z","timestamp":1758073227000},"page":"101840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Euglycemic Diabetic Ketoacidosis and Its Prevention in Elective Surgical Patients Taking Sodium-Glucose Linked Transporter 2 Inhibitors: An International Perspective"],"prefix":"10.1016","volume":"35","author":[{"given":"James H.J.","family":"Selbie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Hiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.artd.2025.101840_bib1","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/dc18-0588","article-title":"SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management","volume":"41","author":"Van Baar","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.artd.2025.101840_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1254\/fpj.145.36","article-title":"Pharmacological and clinical profile of ipragliflozin (suglat\u00ae): a new therapeutic agent for type 2 diabetes","volume":"145","author":"Takasu","year":"2015","journal-title":"Pharmacologica Japonica"},{"key":"10.1016\/j.artd.2025.101840_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejps.2016.08.025","article-title":"Sodium glucose CoTransporter 2 (SGLT2) inhibitors: current status and future perspective","volume":"10","author":"Madaan","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.artd.2025.101840_bib20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s13300-020-00789-y","article-title":"Basic and clinical pharmaco-therapeutics of SGLT2 inhibitors: a contemporary update","volume":"11","author":"Kalra","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.artd.2025.101840_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106031","article-title":"A review on the molecular mechanisms, the therapeutic treatment including the potential of herbs and natural products, and target prediction of obesity-associated colorectal cancer","volume":"175","author":"Yang","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.artd.2025.101840_bib27","article-title":"A review of sotagliflozin for use in type 1 diabetes","volume":"26","author":"Nuffer","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.artd.2025.101840_bib28","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s00044-024-03274-4","article-title":"Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"33","author":"Bassett","year":"2024","journal-title":"Med Chem Res"},{"key":"10.1016\/j.artd.2025.101840_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","article-title":"SGLT2 inhibitors and their mode of action in heart failure\u2014has the mystery been unravelled?","volume":"18","author":"Pabel","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.artd.2025.101840_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc23-1163","article-title":"Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction","volume":"47","author":"Umapathysivam","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.artd.2025.101840_bib4","first-page":"1570","article-title":"Postoperative ketoacidosis with hypoglycemia in a nondiabetic patient taking dapagliflozin for heart failure: a case report","volume":"16","author":"Seki","year":"2022","journal-title":"A A Pract"},{"key":"10.1016\/j.artd.2025.101840_bib21","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.artd.2025.101840_bib22","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.artd.2025.101840_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.artd.2025.101840_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bja.2019.03.028","article-title":"Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review","volume":"123","author":"Thiruvenkatarajan","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.artd.2025.101840_bib7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/anae.13233","article-title":"Peri-operative management of the surgical patient with diabetes 2015: Association of anaesthetists of Great Britain and Ireland","volume":"70","author":"Barker","year":"2015","journal-title":"Anaesthesia"},{"key":"10.1016\/j.artd.2025.101840_bib18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American association of clinical endocrinologists and American college of endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.artd.2025.101840_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2337\/dc22-S016","article-title":"Diabetes care in the hospital: standards of medical care in diabetes","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.artd.2025.101840_bib11","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","article-title":"ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery","volume":"43","author":"Halvorsen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.artd.2025.101840_bib14","first-page":"17","article-title":"Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma","volume":"4","author":"Rawla","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.artd.2025.101840_bib15","first-page":"2965","article-title":"A literature review of the therapeutic perspectives of sodium glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis","volume":"14","author":"Patel","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.artd.2025.101840_bib16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/anae.14251","article-title":"Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations","volume":"73","author":"Milder","year":"2018","journal-title":"Anaesthesia"},{"key":"10.1016\/j.artd.2025.101840_bib17","first-page":"425","article-title":"Perioperative cessation of sodium-glucose cotransporter-2 inhibitors: 72 hours or seven days?","volume":"46","author":"Tan","year":"2018","journal-title":"Anaesth Intensive Care"}],"container-title":["Arthroplasty Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352344125002274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352344125002274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:35:17Z","timestamp":1772904917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352344125002274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":22,"alternative-id":["S2352344125002274"],"URL":"https:\/\/doi.org\/10.1016\/j.artd.2025.101840","relation":{},"ISSN":["2352-3441"],"issn-type":[{"value":"2352-3441","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Euglycemic Diabetic Ketoacidosis and Its Prevention in Elective Surgical Patients Taking Sodium-Glucose Linked Transporter 2 Inhibitors: An International Perspective","name":"articletitle","label":"Article Title"},{"value":"Arthroplasty Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.artd.2025.101840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Inc. on behalf of The American Association of Hip and Knee Surgeons\u00e9","name":"copyright","label":"Copyright"}],"article-number":"101840"}}